甲氨蝶呤治疗后原发性肝脏其他医源性免疫缺陷相关淋巴细胞增生性疾病。

Yasuki Hatayama, Harutoshi Sugiyama, Daisuke Murakami, Hirotaka Oura, Yukiko Shima, Miho Shirato, Takayoshi Nishino, Tadao Nakazawa, Kenichi Suehiro, Makoto Arai
{"title":"甲氨蝶呤治疗后原发性肝脏其他医源性免疫缺陷相关淋巴细胞增生性疾病。","authors":"Yasuki Hatayama,&nbsp;Harutoshi Sugiyama,&nbsp;Daisuke Murakami,&nbsp;Hirotaka Oura,&nbsp;Yukiko Shima,&nbsp;Miho Shirato,&nbsp;Takayoshi Nishino,&nbsp;Tadao Nakazawa,&nbsp;Kenichi Suehiro,&nbsp;Makoto Arai","doi":"10.14740/jmc4135","DOIUrl":null,"url":null,"abstract":"<p><p>Prior reports described cases of lymphoproliferative diseases occurring after methotrexate (MTX) administration, which are called methotrexate-associated lymphoproliferative disorders (MTX-LPDs). It has become clear that these lymphoproliferative diseases also occur following treatment with other immunosuppressive drugs, and they have been termed as other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPDs). In most of these cases, the duration of immunosuppressive drugs is very long, on the order of years. In the present study, we evaluated the development of lymphoproliferative disease despite the short duration of immunosuppressive treatment and determined the tumor doubling time. A 71-year-old woman was diagnosed with adult-onset Still's disease. The patient was administered prednisone 30 mg per day starting on February 25, 2022 and MTX 6 mg per week starting 2 weeks later. Because she was a hepatitis B virus (HBV) carrier, nucleic acid analog therapy was also started to prevent HBV activation. Eight weeks later, biweekly tocilizumab was started. After 5 months of MTX administration, a solitary liver tumor measuring 37 × 32 mm<sup>2</sup> was detected. Three months later, repeat computed tomography revealed that the liver tumor had grown rapidly to 7 cm in diameter. We considered the possibility of OIIA-LPDs and stopped MTX therapy. Biopsy specimens of the liver tumor exhibited lymphocyte proliferation, which was consistent with OIIA-LPDs. The doubling time for tumor growth was 33 days. Despite withdrawing MTX for 6 weeks, the tumor continued to grow, and thus, the patient was referred to the hematology unit. In previously reported cases of MTX-LPDs of hepatic origin, the average duration of MTX administration was 7.3 (2 - 13) years. This report describes a primary hepatic OIIA-LPDs-associated tumor that rapidly increased in size after an extremely short period of MTX administration.</p>","PeriodicalId":16279,"journal":{"name":"Journal of Medical Cases","volume":"14 8","pages":"282-288"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d0/c2/jmc-14-282.PMC10482596.pdf","citationCount":"0","resultStr":"{\"title\":\"Primary Hepatic Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders After Methotrexate Therapy.\",\"authors\":\"Yasuki Hatayama,&nbsp;Harutoshi Sugiyama,&nbsp;Daisuke Murakami,&nbsp;Hirotaka Oura,&nbsp;Yukiko Shima,&nbsp;Miho Shirato,&nbsp;Takayoshi Nishino,&nbsp;Tadao Nakazawa,&nbsp;Kenichi Suehiro,&nbsp;Makoto Arai\",\"doi\":\"10.14740/jmc4135\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Prior reports described cases of lymphoproliferative diseases occurring after methotrexate (MTX) administration, which are called methotrexate-associated lymphoproliferative disorders (MTX-LPDs). It has become clear that these lymphoproliferative diseases also occur following treatment with other immunosuppressive drugs, and they have been termed as other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPDs). In most of these cases, the duration of immunosuppressive drugs is very long, on the order of years. In the present study, we evaluated the development of lymphoproliferative disease despite the short duration of immunosuppressive treatment and determined the tumor doubling time. A 71-year-old woman was diagnosed with adult-onset Still's disease. The patient was administered prednisone 30 mg per day starting on February 25, 2022 and MTX 6 mg per week starting 2 weeks later. Because she was a hepatitis B virus (HBV) carrier, nucleic acid analog therapy was also started to prevent HBV activation. Eight weeks later, biweekly tocilizumab was started. After 5 months of MTX administration, a solitary liver tumor measuring 37 × 32 mm<sup>2</sup> was detected. Three months later, repeat computed tomography revealed that the liver tumor had grown rapidly to 7 cm in diameter. We considered the possibility of OIIA-LPDs and stopped MTX therapy. Biopsy specimens of the liver tumor exhibited lymphocyte proliferation, which was consistent with OIIA-LPDs. The doubling time for tumor growth was 33 days. Despite withdrawing MTX for 6 weeks, the tumor continued to grow, and thus, the patient was referred to the hematology unit. In previously reported cases of MTX-LPDs of hepatic origin, the average duration of MTX administration was 7.3 (2 - 13) years. This report describes a primary hepatic OIIA-LPDs-associated tumor that rapidly increased in size after an extremely short period of MTX administration.</p>\",\"PeriodicalId\":16279,\"journal\":{\"name\":\"Journal of Medical Cases\",\"volume\":\"14 8\",\"pages\":\"282-288\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d0/c2/jmc-14-282.PMC10482596.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medical Cases\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14740/jmc4135\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medical Cases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/jmc4135","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

先前的报告描述了甲氨蝶呤(MTX)给药后发生的淋巴细胞增生性疾病,称为甲氨蝶呤相关淋巴细胞增生性疾病(MTX- lpd)。很明显,这些淋巴增生性疾病也会在其他免疫抑制药物治疗后发生,它们被称为其他医源性免疫缺陷相关淋巴增生性疾病(olia - lpd)。在大多数情况下,免疫抑制药物的持续时间很长,大约几年。在本研究中,我们评估了淋巴增生性疾病的发展,尽管免疫抑制治疗的时间很短,并确定了肿瘤的倍增时间。一名71岁的妇女被诊断患有成人发病的斯蒂尔氏病。患者于2022年2月25日开始给予强的松30毫克/天,2周后开始给予MTX 6毫克/周。由于她是乙型肝炎病毒(HBV)携带者,核酸类似物治疗也开始防止HBV活化。8周后,开始每两周使用一次托珠单抗。给予甲氨蝶呤5个月后,发现一个37 × 32 mm2的孤立性肝脏肿瘤。三个月后,复查计算机断层扫描显示肝脏肿瘤迅速生长到直径7厘米。我们考虑了oia - lpd的可能性并停止了MTX治疗。肝肿瘤活检标本显示淋巴细胞增生,与oia - lpd一致。肿瘤生长倍增时间为33 d。尽管停用MTX 6周,肿瘤仍继续生长,因此,患者被转至血液科。在先前报道的肝源性MTX- lpd病例中,MTX给药的平均持续时间为7.3(2 - 13)年。本报告描述了一个原发性肝脏oia - lpd相关肿瘤,在极短时间的MTX治疗后,肿瘤体积迅速增大。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Primary Hepatic Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders After Methotrexate Therapy.

Primary Hepatic Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders After Methotrexate Therapy.

Primary Hepatic Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders After Methotrexate Therapy.

Prior reports described cases of lymphoproliferative diseases occurring after methotrexate (MTX) administration, which are called methotrexate-associated lymphoproliferative disorders (MTX-LPDs). It has become clear that these lymphoproliferative diseases also occur following treatment with other immunosuppressive drugs, and they have been termed as other iatrogenic immunodeficiency-associated lymphoproliferative disorders (OIIA-LPDs). In most of these cases, the duration of immunosuppressive drugs is very long, on the order of years. In the present study, we evaluated the development of lymphoproliferative disease despite the short duration of immunosuppressive treatment and determined the tumor doubling time. A 71-year-old woman was diagnosed with adult-onset Still's disease. The patient was administered prednisone 30 mg per day starting on February 25, 2022 and MTX 6 mg per week starting 2 weeks later. Because she was a hepatitis B virus (HBV) carrier, nucleic acid analog therapy was also started to prevent HBV activation. Eight weeks later, biweekly tocilizumab was started. After 5 months of MTX administration, a solitary liver tumor measuring 37 × 32 mm2 was detected. Three months later, repeat computed tomography revealed that the liver tumor had grown rapidly to 7 cm in diameter. We considered the possibility of OIIA-LPDs and stopped MTX therapy. Biopsy specimens of the liver tumor exhibited lymphocyte proliferation, which was consistent with OIIA-LPDs. The doubling time for tumor growth was 33 days. Despite withdrawing MTX for 6 weeks, the tumor continued to grow, and thus, the patient was referred to the hematology unit. In previously reported cases of MTX-LPDs of hepatic origin, the average duration of MTX administration was 7.3 (2 - 13) years. This report describes a primary hepatic OIIA-LPDs-associated tumor that rapidly increased in size after an extremely short period of MTX administration.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信